CTI BioPharma (CTIC) Scheduled to Post Quarterly Earnings on Thursday

CTI BioPharma (NASDAQ:CTIC) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 1st. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

CTI BioPharma (NASDAQ:CTIC) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.03. The business had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $0.30 million. CTI BioPharma had a negative return on equity of 90.92% and a negative net margin of 313.77%. On average, analysts expect CTI BioPharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:CTIC opened at $1.71 on Wednesday. The firm has a market cap of $102.64 million, a price-to-earnings ratio of -1.38 and a beta of -0.65. CTI BioPharma has a 12-month low of $1.66 and a 12-month high of $5.36. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.28 and a quick ratio of 4.28.

A hedge fund recently raised its stake in CTI BioPharma stock. Bank of New York Mellon Corp lifted its holdings in CTI BioPharma Corp (NASDAQ:CTIC) by 203.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,671 shares of the biopharmaceutical company’s stock after purchasing an additional 101,055 shares during the quarter. Bank of New York Mellon Corp owned 0.26% of CTI BioPharma worth $750,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 69.47% of the company’s stock.

CTIC has been the subject of several recent analyst reports. Cann restated a “buy” rating and issued a $4.00 price target on shares of CTI BioPharma in a research note on Monday, October 1st. Jefferies Financial Group restated a “buy” rating and issued a $4.00 price target on shares of CTI BioPharma in a research note on Friday, July 20th. BidaskClub cut CTI BioPharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 14th. JMP Securities set a $8.00 price target on CTI BioPharma and gave the stock a “buy” rating in a research note on Tuesday, July 10th. Finally, Zacks Investment Research upgraded CTI BioPharma from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. CTI BioPharma has an average rating of “Buy” and a consensus target price of $5.67.

About CTI BioPharma

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Featured Article: How can you know how many shares are floating?

Earnings History for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply